Bolt Biotherapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Bolt Biotherapeutics Stock-Based Compensation Growth & History (BOLT)
Bolt Biotherapeutics's stock-based compensation was $2.8M for fiscal 2025.
View full Bolt Biotherapeutics company overviewBolt Biotherapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.8M | −$4.6M | −62.44% |
| 2024 | 2024-12-31 | $7.4M | −$1.8M | −19.69% |
| 2023 | 2023-12-31 | $9.2M | −$353,000 | −3.69% |
| 2022 | 2022-12-31 | $9.6M | $1.1M | +12.66% |
| 2021 | 2021-12-31 | $8.5M | $7.1M | +498.59% |
| 2020 | 2020-12-31 | $1.4M | — | — |
Bolt Biotherapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $552,000 | −$73,000 | −11.68% |
| Q1 2026 | 2026-03-31 | $545,000 | −$164,000 | −23.13% |
| Q4 2025 | 2025-12-31 | $1.0M | −$141,000 | −11.93% |
| Q3 2025 | 2025-09-30 | $407,000 | −$691,000 | −62.93% |
| Q2 2025 | 2025-06-30 | $625,000 | −$2.2M | −77.88% |
| Q1 2025 | 2025-03-31 | $709,000 | −$1.6M | −69.20% |
| Q4 2024 | 2024-12-31 | $1.2M | −$886,000 | −42.84% |
| Q3 2024 | 2024-09-30 | $1.1M | −$1.2M | −52.86% |
| Q2 2024 | 2024-06-30 | $2.8M | $475,000 | +20.21% |
| Q1 2024 | 2024-03-31 | $2.3M | −$174,000 | −7.03% |
| Q4 2023 | 2023-12-31 | $2.1M | −$55,000 | −2.59% |
| Q3 2023 | 2023-09-30 | $2.3M | $186,000 | +8.68% |
| Q2 2023 | 2023-06-30 | $2.4M | −$41,000 | −1.71% |
| Q1 2023 | 2023-03-31 | $2.5M | −$443,000 | −15.18% |
| Q4 2022 | 2022-12-31 | $2.1M | −$19,000 | −0.89% |
| Q3 2022 | 2022-09-30 | $2.1M | −$83,000 | −3.73% |
| Q2 2022 | 2022-06-30 | $2.4M | $368,000 | +18.19% |
| Q1 2022 | 2022-03-31 | $2.9M | $810,000 | +38.41% |
| Q4 2021 | 2021-12-31 | $2.1M | $1.6M | +276.45% |
| Q3 2021 | 2021-09-30 | $2.2M | $1.8M | +452.36% |
| Q2 2021 | 2021-06-30 | $2.0M | $1.8M | +807.17% |
| Q1 2021 | 2021-03-31 | $2.1M | $1.9M | +837.33% |
| Q4 2020 | 2020-12-31 | $569,000 | — | — |
| Q3 2020 | 2020-09-30 | $403,000 | — | — |
| Q2 2020 | 2020-06-30 | $223,000 | — | — |
| Q1 2020 | 2020-03-31 | $225,000 | — | — |
Bolt Biotherapeutics stock-based compensation trends
Over the last five fiscal years, Bolt Biotherapeutics's stock-based compensation increased from $1.4M to $2.8M, a change of $1.4M. The latest reported quarter, Q2 2026, shows $552,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bolt Biotherapeutics source filings ↗